ResMed's Tariff Exemption Should Support Multiples -- Market Talk

Dow Jones

2025/04/28

0120 GMT - ResMed's bull at Macquarie expects its U.S. tariff exemption to help reverse the stock's recent compression in valuation multiples. The investment bank's analysts don't think the breath-tech manufacturer will feel any material impact from U.S. tariffs, and reiterate their outperform rating on the stock. New products, margin expansion, cash flow and capital deployment should also help grow multiples back toward previous levels, they add. In a note to clients, the analysts point out that stronger-than-expected mask sales and softer-than-expected device sales meant that 3Q U.S. revenue was in line with expectations. Macquarie trims its target price 1.6% to A$48.00. Shares are up 2.8% at A$37.075. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

April 27, 2025 21:20 ET (01:20 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2530952894"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530952894\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2530952894?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-28 09:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530952894","market":"nz","top_or_hot":-1,"title":"ResMed's Tariff Exemption Should Support Multiples -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0120 GMT - ResMed's bull at <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> expects its U.S. tariff exemption to help reverse the stock's recent compression in valuation multiples. The investment bank's analysts don't think the breath-tech manufacturer will feel any material impact from U.S. tariffs, and reiterate their outperform rating on the stock. New products, margin expansion, cash flow and capital deployment should also help grow multiples back toward previous levels, they add. In a note to clients, the analysts point out that stronger-than-expected mask sales and softer-than-expected device sales meant that 3Q U.S. revenue was in line with expectations. Macquarie trims its target price 1.6% to A$48.00. Shares are up 2.8% at A$37.075. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2025 21:20 ET (01:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed's Tariff Exemption Should Support Multiples -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed's Tariff Exemption Should Support Multiples -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-28 09:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0120 GMT - ResMed's bull at <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> expects its U.S. tariff exemption to help reverse the stock's recent compression in valuation multiples. The investment bank's analysts don't think the breath-tech manufacturer will feel any material impact from U.S. tariffs, and reiterate their outperform rating on the stock. New products, margin expansion, cash flow and capital deployment should also help grow multiples back toward previous levels, they add. In a note to clients, the analysts point out that stronger-than-expected mask sales and softer-than-expected device sales meant that 3Q U.S. revenue was in line with expectations. Macquarie trims its target price 1.6% to A$48.00. Shares are up 2.8% at A$37.075. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2025 21:20 ET (01:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7501","symbol_name":"新冠治疗股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2530952894","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530952894","pubTimestamp":1745803200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0120 GMT - ResMed's bull at Macquarie expects its U.S. tariff exemption to help reverse the stock's recent compression in valuation multiples. The investment bank's analysts don't think the breath-tech manufacturer will feel any material impact from U.S. tariffs, and reiterate their outperform rating on the stock. New products, margin expansion, cash flow and capital deployment should also help grow multiples back toward previous levels, they add. In a note to clients, the analysts point out that stronger-than-expected mask sales and softer-than-expected device sales meant that 3Q U.S. revenue was in line with expectations. Macquarie trims its target price 1.6% to A$48.00. Shares are up 2.8% at A$37.075. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7501":"新冠治疗股","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK7007":"医疗保健设备","BK4588":"碎股","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","RMD.AU":"Resmed DRC","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","RMD":"瑞思迈","BK4504":"桥水持仓"},"translate_title":"瑞思迈的关税豁免应该会支持倍数——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":1,"RMD.AU":0.9},"content_text":"0120 GMT - ResMed's bull at Macquarie expects its U.S. tariff exemption to help reverse the stock's recent compression in valuation multiples. The investment bank's analysts don't think the breath-tech manufacturer will feel any material impact from U.S. tariffs, and reiterate their outperform rating on the stock. New products, margin expansion, cash flow and capital deployment should also help grow multiples back toward previous levels, they add. In a note to clients, the analysts point out that stronger-than-expected mask sales and softer-than-expected device sales meant that 3Q U.S. revenue was in line with expectations. Macquarie trims its target price 1.6% to A$48.00. Shares are up 2.8% at A$37.075. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2025 21:20 ET (01:20 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}